Returns on pharmaceutical R&D improving as pipelines revive

LONDON, Dec 10 (Reuters) - Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development (R&D) increasing for the first time since 2010.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.